Minimum inhibitory concentration (MIC) in μg mL−1 of HSD1835 against highly resistant MRSA clinical strains.
| Strain | MRSA description | ||||||
|---|---|---|---|---|---|---|---|
| PFGE pattern/MLST typea | spa type eGenomics (Ridom) | SCCmec | Other genetic characterizationa | Additional non MRSA resistance (dru type)a | HSD1835 MIC (μg mL−1) | Oxacillin MIC (μg mL−1) | |
| ARLG 1561 | USA300 | 1 | IVa | ACME+, pvl genes+ | Ery | 2 | NT |
| ARLG 1567 | USA300 | 1 | IVa | ACME+, pvl genes+ | Ery, Cipro | 2 | NT |
| ARLG 1568 | USA300 | 1 | IVa | ACME+, pvl genes+, MupA gene+ | Mup, Ery, Cipro | 2 | NT |
| ARLG 1569 | USA300 | 1 | IVa | ACME+, pvl genes+, MupA gene+ | Mup, Ery, Cipro, Clinda | 2 | NT |
| ARLG 1570 | USA300 | 1 | IVa | ACME+, pvl genes+, MupA gene+ | Mup, Ery, Cipro, Clinda | 2 | NT |
| ARLG-1644 | ST239 | 351 (t030) | 3A.1.4 | ccrC+, dcs+, Hg-J+, mecl+ | (dt10a) | 2 | 512 |
| ARLG-1649 | ST1312 | 351 (t030) | 3A.1.4 | ccrC+, dcs+, Hg-J+, mecl+ | (dt10g) | 2 | 256 |
| ARLG-1663 | ST239 | 351 (t030) | 16 691 | ccrC+, Hg-J+, mecl+ | (dt9x) | 1 | 256 |
| ARLG-1665 | ST239 | 351 (t030) | 16 691 | ccrC+, Hg-J+, mecl+ | (dt9x) | 2 | 512 |
a
ACME = arginine catabolic mobile element, PFGE = pulsed field gel electrophoresis, MLST = multilocus sequence typing, pvl = Panton–Valentin leukocidin, Ery = erythromycin, Mup = mupirocin, Cipro = ciprofloxacin, Clinda = constitutive clindamycin resistance, dru = direct repeat unit, ARLG = Antibacterial Resistance Leadership Group, NT = Not Tested.